France Ginchereau Sowell

France Ginchereau Sowell

Auto-generated profile, based on publicly available information

France Ginchereau Sowell

IQVIA, New York, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
HOHolly K. K. O’Donnell
Holly K. K. O’Donnell
KSKimber M. Simmons
Kimber M. Simmons
SGStephen E. Gitelman
Stephen E. Gitelman
TDTerry Dex
Terry Dex
RHRobert Hill
Robert Hill
KHKorey K. Hood
Korey K. Hood
Aims: This study surveyed individuals and caregivers of children who received teplizumab at stage 2 type 1 diabetes (T1D) to garner real‐world experiences and their health outlook for the future following treatment with the first approved disease‐modifying immune therapy for delaying the onset of Stage 3 T1D. Materials and Methods: This was a cross‐sectional, observational, online survey (conducted September–October 2024) of adults (≥18 years) and caregivers of children (8–17 years) who received teplizumab while participating in the US COMPASS patient support program. Questions pertained to demographics, health history, T1D screening, the decision to take teplizumab, treatment, post‐treatment experience, outlook on prognosis and self‐reported health status. All data were summarized using descriptive statistics. Results: A total of 47/116 invited individuals responded (30 adults, 17 caregivers of children). Almost half of respondents had a family history of T1D, and 36% reported autoimmune comorbidities. The top reason for both screening for T1D and receiving teplizumab was for a chance at delaying Stage 3 T1D. Although respondents expressed continued concern over diabetes progression, 87% felt grateful to receive teplizumab, 72% felt it would help slow down the disease, 60% felt it would make T1D easier to manage and most (>80%) would recommend treatment/make the same decision for another family member. Conclusions: Individuals living with or caring for someone who received teplizumab felt grateful for the opportunity to delay disease or make it easier to manage following teplizumab, with most agreeing they would recommend teplizumab and make the same decision for family in their situation. Plain Language Summary: Type 1 diabetes (T1D) happens when the body destroys cells in the pancreas that make insulin. This ultimately causes high blood sugar. People with T1D often worry about the long‐term effects of the disease. Teplizumab is the first FDA‐approved treatment that delays the onset of high blood sugar in people in the early stages of T1D—when there are signs of cell damage and mild increases in blood sugar. We surveyed adults ( N = 30) and caregivers ( N = 17) of children treated with teplizumab about their journey before and after treatment. More than half of adults were initially told they might have a different type of diabetes, usually type 2, before being accurately diagnosed with early‐stage T1D. Doctors specializing in diabetes were most often the ones who recommended screening for T1D. The most common reason to screen was a chance for more time before the onset of high blood sugar. Greater than 80% of people were grateful they or their child had the opportunity to receive teplizumab, and most would recommend it to others in a similar situation. After receiving teplizumab, most people still worried about their blood sugar and measured it frequently. Most thought that teplizumab would delay the disease progression to symptoms, and more than half thought teplizumab would make T1D easier to manage. These findings are the first to describe the journey of adults and caregivers of children treated with teplizumab, their reasons for screening, and their beliefs about the future.

29 October 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
NANuzhat Afroz
Nuzhat Afroz
ECEliazar Sabater Cabrera
Eliazar Sabater Cabrera
MRMatthew Reaney
Matthew Reaney
FSFrance Ginchereau Sowell
France Ginchereau Sowell
OOObinna Onwude
Obinna Onwude
Introduction Invasive meningococcal disease (IMD) has a low incidence but is a life-threatening illness that is preventable via vaccination. Even with treatment, up to 10–15% of cases are fatal, and many survivors may experience severe long-term sequelae. Building upon the acute-phase findings presented in the Part 1 manuscript for this study, we describe the long-term physical, social, psychological, and economic burden of IMD on US survivors and their caregivers in this Part 2 manuscript. Methods This was a novel, non-interventional, mixed-methods study among US survivors and their caregivers using a bespoke survey and qualitative interviews. Results Ten adult survivors, one adolescent survivor, and three caregivers participated in this study. Survivors described extensive physical, neurological, and systemic sequelae, including difficulty walking (11/11), repeat secondary infections (9/11), and numbness (6/11), among others, which were echoed by caregivers. Survivors shared that IMD had negatively impacted their long-term quality of life, citing long-term impacts including emotional impacts (11/11), social impacts (10/11), memory (7/11) and attention (5/11) problems, and difficulty with functional (10/11), self-care (7/11), and physical (6/11) activities. Caregivers were also impacted, describing emotional trauma (3/3), sleep problems (2/3), and day-to-day challenges (2/3). Long-term financial challenges related to healthcare resource utilization were substantial, with specialized care and rehabilitation therapy expenses (11/11), insurance challenges (8/11), and high out-of-pocket costs (6/11) for survivors. Productivity losses were also commonly described by survivors (9/11); sequelae hindered ability to attend school (9/11) or work full time (8/11). Caregivers (2/3) described taking leave from their employment, affecting family income. Conclusions The humanistic burden of IMD on survivors and their caregivers is substantial and persistent. A comprehensive approach, including preventative measures (e.g., vaccination) and long-term medical, psychological, and financial support for those affected, is needed to mitigate the burden of IMD. A video abstract is available with this article. Video abstract (MP4 1,17,430 kb)

29 October 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
NANuzhat Afroz
Nuzhat Afroz
ECEliazar Sabater Cabrera
Eliazar Sabater Cabrera
MRMatthew Reaney
Matthew Reaney
FSFrance Ginchereau Sowell
France Ginchereau Sowell
OOObinna Onwude
Obinna Onwude
Introduction Invasive meningococcal disease (IMD) has a low incidence but is a life-threatening illness with a 10–15% mortality rate. Even with timely treatment, survivors may experience acute and long-term health complications. While meningococcal vaccines are recommended for adolescents and young adults in the USA, vaccination coverage remains uneven across serotypes. This study investigated the physical, social, psychological, and economic burden of IMD on survivors and their caregivers in the USA during the acute phase (Part 1, presented in this manuscript) and the long-term phase (Part 2, presented in a separate manuscript) of IMD. Methods This study implemented a non-interventional, mixed-methods approach using a bespoke survey and qualitative interviews (designed on the basis of a preliminary conceptual model of IMD) with US survivors and their caregivers. Results A total of 11 survivors (1 adolescent, 10 adults) and 3 caregivers participated in the study. Survivors contracted IMD during infancy (n = 2), childhood (n = 3), or adulthood (n = 6), and often described leading healthy lives pre-IMD. At IMD onset, interactions with the healthcare system impacted participants’ experiences; confusion and care delays were common, and procedures were often invasive (e.g., amputations). Survivors commonly experienced symptoms including skin rash (7/11), fever (6/11), and unconsciousness (6/11), consistent with caregivers’ reports. Survivors able to report on the short-term impacts of IMD (n = 9) described functional limitations (9/9), emotional impacts (6/9) such as fear and trauma, and school (6/9), work (4/9), and financial (5/9) challenges. Caregivers also experienced emotional impacts (3/3) and family (2/3), work (3/3), and financial (3/3) impacts during the acute phase. Conclusions IMD places a significant humanistic burden on survivors and their caregivers during the acute phase. Results from Part 1 of this study indicate a need for increased disease awareness and healthcare provider education, expeditious diagnosis, and improved access to prevention methods such as available meningococcal vaccines. A video abstract is available with this article. Video abstract (MP4 1,24,432 kb)

4 March 2026 in Current Medical Research and Opinion
Verified
Journal Article
Open access
ZRZoe Raglow
Zoe Raglow
DKDan Kaul
Dan Kaul
ARAna María Rodriguez
Ana María Rodriguez
AGAna Sofia Oliveira Gonçalves
Ana Sofia Oliveira Gonçalves
MHMickael Henry-Szatkowski
Mickael Henry-Szatkowski
BSBob G. Schultz
Bob G. Schultz
Post-transplant cytomegalovirus (CMV) infection is one of the most common viral infections experienced by transplant recipients1,2. Despite prevention strategies, CMV infection continues to occur w...